Original Report therapeutic group premiums. 3, 5 The PBS is designed to improve equitable access to medicines; it has a progressive cost-sharing system whereby those with limited financial resources (concession patients) pay a lower copayment than that paid by general patients. Affordability is further protected by the operation of a safety net. 6 Despite these protections, copayments in Australia are high by international standards. 5 The entire cost of prescriptions for non-PBS listed prescription medications and over-the-counter (OTC) medicines is usually the responsibility of the patient. The increased need for supportive OTC medications (such as mouthwashes, skin creams, and supplementary nutrition) to help manage the side-effects of cancer treatment, 7 and the substantial associated costs could have an impact on the degree to which people fully access health care. In 2009, the Australian Bureau of Statistics (ABS) reported that 9% of adult Australians reported delaying or not filling prescriptions because of cost. 8 A recent study of disadvantaged Australians found almost half (47%) of the sample reported delayed or nonuse of medicines as a result of cost. 9 The cost of cancer medicines may prove prohibitive for some patients, which could reduce the ability of a health system to fully deliver best practice care.
Patient medication adherence affects cancer treatment effectiveness and treatment response. [10] [11] [12] [13] [14] Nonuse of prescribed cancer medicines is also associated with increased physician visits, higher rates of hospitalisation, longer average length of time spent in hospital for cancer patients 12, 15, 16 and higher health service costs. 15, 17 In Australia, little is known about the proportion of cancer patients who do not take prescribed or recommended medications as a result of cost-related factors. The importance of this issue is reflected in the position statements of cancer advocacy groups. 18, 19 The affordability of medicines for cancer patients and survivors can be affected by pre-diagnosis sociodemographic factors, but is also likely to be affected by the impacts of the disease or treatment on an individual's employment status and financial situation. Data from Ireland 7 and the United States 20 have highlighted this issue, finding a significant reduction in income for cancer patients and survivors. Internationally, cancer reduces employment rates by 27% on average. 4 Similarly, in Australia, having cancer reduces the probability of employment by 29% in men and 24% in women. 4 Despite initiatives designed to assist patients in defraying cancer costs, there remains the possibility that some patients with limited financial resources -either before their diagnosis or as a result of having cancer -may find prescription medicines unobtainable due to cost. A clearer understanding would inform the policy discussion on how to minimise the barriers for cancer patients' access to potentially life-saving medicines.
The aims of the study were to identify the proportion of patients who did not use or did not purchase cancer-related medicines due to cost; the degree to which prescribed medicines for cancer were considered a financial burden; and patient-related factors (sociodemographic characteristics, disease, treatment characteristics, and recruitment location) associated with nonuse of medicines or perceived financial burden. A cross-sectional self-report survey was completed by outpatients attending for treatment or appointments at Australian oncology clinics. To represent a range of patient experiences relating to geographic location, patient volume and models of service delivery the study involved 2 metropolitan hospitals; 1 in a regional New South Wales city, and 1 in a Victorian capital city. Data were collected during January-July 2014.
Method
Adults with a confirmed diagnosis of cancer and at least one previous clinic appointment were invited by a trained research assistant to complete the 30-minute pen-and-paper core questionnaire when presenting for an outpatient medical oncology consultation. Patients who did not speak English, were physically or mentally incapable of completing the questionnaire, or unable to provide informed consent were not eligible for the study. The age and gender of nonconsenters were collected to assess consent bias. Consenting participants were mailed a follow-up questionnaire, which contained the medicine affordability items 4 weeks after completion of the core questionnaire. If no response was received, then reminder letters were sent at 3 and 6 weeks later.
Measure
Demographic characteristics (core questionnaire). Age, gender, education, marital status, country of birth, employment status, private health insurance status, having a concession card, smoking status (Table 1 ). In Australia, holding private health insurance is an indicator of higher socioeconomic status and the likelihood of using private health services, which incur an out of pocket cost. Having a concession card is an indicator of low income.
Disease and treatment characteristics (core questionnaire). Cancer type, time since diagnosis, current treatment, and treatment location.
Medicine affordability (follow-up questionnaire). A subset of items from previous studies were used to assess medicine affordability (Table 2) . 5 Participants were asked:
n Over the past 3 months, have you used any medicines including prescription and over-the-counter medicines? Answer options Yes/No n Over the past 3 months, because of costs, have you:
n Bought over-the-counter-medicines rather than get prescription medicine from your doctor? n Asked your doctor or pharmacist for a cheaper generic version of a prescribed medicine? n Used medicines you have had at home rather than obtain a new prescription? n Used a medicine belonging to someone else rather than obtain a new prescription Answer options Item response categories distinguished between cancer-speci c (Yes, for my cancer treatment or recovery) and noncancer speci c medications (Yes, but not for my cancer treatment or recovery).
n Over the past 3 months, has a doctor, specialist, or nurse practitioner prescribed medication for you? Answer options Yes, and the prescription related to my cancer treatment or recovery; Yes, but the prescription was not related to my cancer treatment or recovery; or No. If the response was Yes, then they were asked: Did you: Obtain all medicines prescribed; Obtain some but not all; or None of the prescribed medicines?
n How much of a nancial burden were the prescribed medicines for your household? Answer options No burden/slight burden; moderate burden; heavy burden; or extreme burden.
e follow-up questionnaire also assessed change in income since cancer diagnosis. Having a concession card is an indicator of being on a low income.
c Fortnightly income before diagnosis; those who were employed before diagnosis (n = 86).
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Analysis
Descriptive statistics (frequencies, proportions, and 95% con dence intervals [CIs]) were calculated for all survey items. Chi-squared or Fisher exact tests were used to explore associations between participant characteristics (sociodemographic characteristics, disease, treatment characteristics, and recruitment location) and each outcome. Participant characteristics with an association of P < .1 were included in a multivariate logistic regression model for each outcome. Location of recruitment (centre 1 vs centre 2) was included in multiple logistic regressions.
Results
Of the 402 patients who were approached to complete the core questionnaire at the 2 sites, 321 (79.9%) completed the core survey and 255 (63.4%) completed the follow-up questionnaire that contained the medicine a ordability items. A higher proportion of women consented to completing the a ordability items (Fisher exact P = .0205), compared with nonconsenters, and no di erence in age was observed between the 2 groups (exact P = .8250). ere were no di erences in age or gender between those who completed the core survey and those who completed the a ordability items in the follow-up survey (exact P = .05).
e demographic and disease characteristics of the participants are listed in Table 1 .
Nonuse or nonpurchase of cancer-related medicines due to cost
In all, 90.8% (227/250; 95% CI, 87.2-94.4) of participants who completed the follow-up questionnaire had used a prescription or OTC medicine in the previous 3 months. As shown in Table 2 , as a result of cost, in the previous 3 months: 9.1% (19/209) had used OTC medicines rather than prescribed medicines for cancer, 17.3% (36/208) had asked for cheaper or generic versions of medicines for cancer, and 3.8% (8/209) had used existing medicine rather than obtain a new prescription for cancer. In addition, 11.8% (25/211) reported at least 1 of the following regarding cancer-related medicines: using OTC rather than prescribed medicine, using medicines they had at home rather than lling a new prescription, or using medicines from someone else.
Of the 255 participants, 119 (46.7%; 95% CI, 40.5-52.8) had medicines prescribed for them solely in relation to their cancer, and another 29 (11.4%; 95% CI, 7.4-15.3) had been prescribed both cancer-related and noncancer-related medicines. For cancer-related prescriptions, 132 of 146 participants (90.4%; 95% CI, 85.6-95.2) reported they had obtained all the prescribed medicines, and 14 of 146 (9.6%;, 95% CI, 4.8-14.4) reported obtaining some but not all of the medicines prescribed. Responses for cancer-related versus noncancer-related medicines seemed to follow a similar pattern, with the exception that asking for a cheaper generic version of the medicine was less likely for cancer-related prescriptions than for other prescriptions.
Financial burden associated with prescribed medicines for cancer
Participant responses to questions about whether the prescribed medicines were a burden for their household are listed in Table 3 . A minority of the participants (52/140, 37.1%) indicated that cancer-related prescriptions were not a burden xxat all, whereas 11.4% (16/140) indicated the cancer-related prescriptions were a heavy or extreme nancial burden.
Patient characteristics associated with nonuse of medicines or perceived nancial burden
Univariate and multivariate analyses indicated that none of the patient sociodemographic or disease characteristics examined were associated with reporting any form of nonuse or nonpurchase of prescribed medicines for cancer.
Responses to the level of perceived burden associated with prescribed medicines for cancer care were grouped into No/Slight Burden compared with Moderate/Heavy/ Extreme Burden. Univariate analyses indicated that age, smoking, and reduced income after diagnosis may have been related to reported burden. A multiple logistic regression analysis indicated that a having a reduced income after being diagnosed with cancer was associated with reporting a heavy or extreme nancial burden due to prescribed medicines for cancer (OR, 3.73; 95% CI, 1.1-12.1; Table 4 ).
Discussion
is study indicated that a small to moderate proportion of patients reported nonuse of medicines that were prescribed as part of their cancer care or recovery. e majority reported that such medicines constituted a nancial burden, particularly for those who had a reduced income after their cancer diagnosis.
Nonuse or underuse of prescribed medicines was reported by fewer than 10% of participants, compared with 3.4% of a general community sample that reported not lling all prescriptions because of cost. 5 Internationally, reports of medicine underuse because of cost in the general population vary from 3% in the Netherlands to 20% in the United States. 21 Una ordable medicines may represent a signi cant loss of health status and wellbeing (eg, through ine ective management of pain or nausea) for the cancer patient or survivor. Nonadherence to prescribed cancer medications may also impinge on the investment already made in the diagnosis and treatment of an individual, resulting in higher downstream costs for both the patient and health provider.
It is worrying that 33.6% of the participants reported experiencing a moderate, heavy, or extreme nancial burden in the 3 months prior to completing the survey because of the cost of their prescribed medicines for cancer treatment or recovery. It is of particular concern that those whose income had been reduced after being diagnosed with cancer had almost 4 times the odds of reporting a heavy/extreme nancial burden associated with prescribed medicines for cancer. e combination of reduced income and increased medication costs may have particularly serious consequences for some patients. e change in nancial situation may occur quite suddenly with little or no opportunity for nancial adjustment to new circumstances. erefore, a change in employment status should constitute a "red ag" to trigger assistance with treatment adherence. Metrics for a change in employment status or reported nancial burden may need to be part of a process to prioritise access to nancial assistance, even for patients who were reasonably well o before their diagnosis. Studies 9 This study, at the very least, identifies that the nonuse of prescribed medications as a result of cost or financial burden is having an impact on access to prescribed cancer care, which in turn highlights potential issues with the implementation of 2 objectives of Australia's National Medicines Policy. 22 The 2 goals listed in the policy are that patients should have "timely access to the medicines that Australians need, at a cost individuals and the community can afford" and that there be "quality use of medicines." These findings suggest that for some, the goal of affordable medicines for individuals is not being met. Similarly, our survey's evidence of nonadherence to prescribed cancer medications suggests some patients, because of cost, are not meeting the goal of quality use of medicines. Greater efforts to limit the costs of prescribed medicines in cancer care -particularly for those on reduced incomes -may reduce the hardship experienced by cancer patients and improve their ability to fully participate in their intended treatment.
Limitations
The study response rate (55%), the choice of medical oncology outpatient clinics as a recruitment location and the use of only 2 hospital sites places limitations on the generalisability of the data to the wider population of cancer patients. Self-reported behaviour may also be subject to a small to moderate level of inaccuracy in the study context. There may also be a potential lack of sensitivity in the response categories for some variables such as time since diagnosis, and age group which may have hindered the ability of the study to identify associations between participant characteristics and the financial impacts of interest to the study. This lack of sensitivity extends to not including percentage of net income or disposable income spent on medicines as a measure, thus the financial burden from the cost of medicines cannot be quantified in this study. The lack of detail about which medicines were underused (such as whether they were chemotherapies or supportive medicines) and to what degree is also a study limitation.
Conclusion
This study provides some of the first Australian data regarding the financial impact of medicine costs on cancer patients and survivors. Greater efforts to limit the costs of prescribed medicines in relation to cancer care -particularly for those on reduced incomes -may reduce the financial hardship experienced by cancer patients.
